OraSure Technologies, Inc. (OSUR) carries thin sell-side coverage, typical of a small-cap diagnostics maker. Only two current, identifiable price targets could be verified. Craig-Hallum initiated coverage on October 23, 2026 with a Buy rating and a $7.00 target, arguing the third quarter marks an inflection point and that mid-teens revenue growth is achievable after twelve consecutive quarters of year-over-year declines. A second, Hold-rated analyst carries a $4.00 target, according to S&P Global data compiled by StockAnalysis; Yahoo Finance lists a matching $5.50 one-year estimate. The arithmetic mean of these two targets is $5.50, which is the central target used here.
The spread from $4.00 to $7.00 — roughly 75% apart — is wide and says more about differing views on timing and terminal valuation than about a simple bull-versus-bear split. Bulls emphasize a stabilizing public-health funding environment and new product catalysts; the more cautious view reflects a company still posting net losses with a modest revenue base.
OraSure closed near $3.53 on November 9, 2026, giving the company a market capitalization of roughly $241 million against an enterprise value near $92 million (reflecting roughly $148 million in cash and negligible debt). The path to $5.50 requires a gain of about 56% — a very large move for a stock already up roughly 45–51% over the past year. The shares sit just above their 200-day moving average near $3.54 but below the 50-day average near $3.73, and $5.50 sits above the 52-week high of $4.58. Reaching it would require the market to re-rate a company that remains unprofitable, with trailing twelve-month EPS (earnings per share) of about -$0.69 and a price-to-sales ratio near 2.1.
OraSure's "return to growth" strategy is beginning to show results. Third-quarter 2026 revenue rose 14% year over year to $30.9 million, with GAAP (Generally Accepted Accounting Principles) gross margin up roughly 170 basis points to 45.2%. The company reported initial commercial orders for its Colli-Pee Dx urine-collection device and its OraQuick Ebola 2.0 rapid antigen test, which received FDA (Food and Drug Administration) emergency use authorization in July 2026. Management reiterated revenue growth for 2026 and expects operating cash flow breakeven entering 2027.
Several catalysts could reinforce the bull case: the ongoing Ebola outbreak response and the BRIDGE Access Platform study led by Africa CDC and WHO; expansion of Sickle SCAN newborn screening; a Health Canada license for the OraQuick HIV self-test; insourcing-driven margin gains; and a large buyback program that has already retired more than 7% of shares outstanding. Activist investor Altai Capital's push for strategic change adds a potential corporate-action catalyst.
The principal obstacles are financial and operational. The company posted a net loss of about $49 million over the trailing twelve months and negative operating cash flow, and it withdrew and delayed its IntelliQ CT/NG (chlamydia/gonorrhea) FDA submission — a setback to a key STI (sexually transmitted infection) testing catalyst. International diagnostics remain sensitive to public-health funding and evolving African procurement pathways that can slow adoption even during urgent outbreaks. A history of sharp revenue declines after the COVID-19 wind-down (revenue fell from roughly $405 million in 2023 to about $115 million in 2025) leaves the market skeptical about sustained growth. Thin coverage also means one cautious revision can meaningfully move the average target.
The stock trades in a broad 52-week range of $2.08 to $4.58. On the downside, the 200-day moving average near $3.54 and the $3.40–$3.50 zone are near-term reference points; a deeper floor sits near the $2.08 low. On the upside, the 52-week high of $4.58 is the first significant resistance level, followed by the psychologically important $5.00 mark. The $5.50 central target would require clearing both — a breakout well beyond the stock's recent trading history rather than a move within established range structure.
Analyst price targets generally reflect a roughly 12-month horizon, and no materially different horizon was stated for OSUR. Because the company has only just reported third-quarter results, near-term monitoring centers on fourth-quarter guidance, revenue-growth sustainability, gross-margin trajectory, and progress toward operating cash flow breakeven in 2027. Investors should also watch any FDA action on the IntelliQ resubmission, the BRIDGE Access study results, Ebola-related order flow, Altai Capital's campaign, and any updates to the buyback program.
AI Daily Buy/Sell Signals from Tickeron use artificial intelligence to continuously monitor thousands of stocks and ETFs (exchange-traded funds) and generate Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a thinly covered, volatile name like OraSure, such signals can help traders discover opportunities, monitor existing positions, and spot changing trends more efficiently than manual screening. Traders exploring OSUR may find these signals a useful complement to fundamental research.
The $5.50 central target is a mathematical average of two analyst views — Craig-Hallum's $7.00 and a $4.00 Hold — rather than a guarantee, and it sits roughly 56% above the current price. Reaching it would require OraSure to sustain its return to revenue growth, expand margins, convert new FDA clearances into commercial orders, and begin closing the gap toward cash flow breakeven, all while the market re-rates a still-unprofitable business. Setbacks such as the IntelliQ delay, funding volatility abroad, and a wide $4.00-to-$7.00 target range argue for caution. Investors should focus on execution, guidance, and regulatory milestones rather than treating the average target as a forecast.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, OSUR has been loosely correlated with IQV. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if OSUR jumps, then IQV could also see price increases.
| Ticker / NAME | Correlation To OSUR | 1D Price Change % | ||
|---|---|---|---|---|
| OSUR | 100% | N/A | ||
| IQV - OSUR | 43% Loosely correlated | -2.21% | ||
| MTD - OSUR | 42% Loosely correlated | +0.46% | ||
| RVTY - OSUR | 41% Loosely correlated | -1.67% | ||
| IART - OSUR | 41% Loosely correlated | +0.35% | ||
| INGN - OSUR | 38% Loosely correlated | +1.25% | ||
More | ||||
| Ticker / NAME | Correlation To OSUR | 1D Price Change % |
|---|---|---|
| OSUR | 100% | N/A |
| Pharmaceuticals: Other industry (49 stocks) | 36% Loosely correlated | +0.20% |
| Pharmaceuticals industry (151 stocks) | -2% Poorly correlated | +0.11% |